Navigation Links
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Date:8/27/2007

ns. In these roles, he managed clinical development activities for a variety of therapeutic areas, including oncology, infectious diseases, women's health, sleep and central nervous system. Prior to Searle/Pharmacia, Dr. Sherman was at Squibb/Bristol-Myers Squibb in Clinical Pharmacology and Clinical Research.

Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed both an internship and residency in internal medicine at the Northwestern University McGaw Medical Center, where he also served as a chief medical resident. In addition, Dr. Sherman completed fellowship training at the University of California, San Francisco (UCSF) and also served as a research associate at the Howard Hughes Medical Institute at UCSF. Dr. Sherman is currently a Board Member of the Drug Information Association (DIA) and will be chairing the DIA 2008 Annual Meeting.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's plans to collect, analyze and submit additional Phase 3 data in an amended NDA for L-MTP-PE and to respond to other matters raised by ODAC and the FDA, the Company's confidence that the proposed NDA amendment will provide substantial evidence for the continued regulatory approval process, the
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... If you plan to attend the 27th annual ... will also want to sign up for the tour of Framingham State University's newest ... a walk through of the (8) chemistry teaching labs that are exclusively utilizing ...
(Date:9/2/2015)... , Sep. 02, 2015 ... has announced the addition of Jain PharmaBiotech,s new ... Companies" to their offering. This ... development of sequencing technologies, and their applications. Current ... as companies developing them. Various applications of sequencing ...
(Date:9/2/2015)... Sep. 02, 2015 Research ... of Jain PharmaBiotech,s new report "Gene Therapy - ... The markets for gene therapy are difficult to ... product and it is marketed in China ... for the years 2014-2024. The estimates are based on ...
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, ... enrolled in the multicenter Phase 2 clinical trial ... long-term treatment of recurrent subfoveal choroidal neovascularization secondary ... is a unique vascular endothelial growth factor (VEGF) ... implant. "This landmark proof-of-concept study will ...
Breaking Biology Technology:Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... Md., July 31 Novavax, Inc. (Nasdaq: NVAX ) ... results in a press release to be issued after 8:00 a.m. ... an investor conference call to discuss its financial results at 10:00 ... be hosted by Novavax President and Chief Executive Officer Dr. Rahul ...
... , ANNAPOLIS, Md., July 31 ... biodefense company developing medical countermeasures against biological and chemical threats, ... on the issuance of 2-year, 10% unsecured senior convertible notes ... placement of approximately $19.3 million. , , ...
... , , , ... (Nasdaq: CRGN ) today reported its financial results for ... reduced its outstanding convertible debt and reached an agreement in principle, ... action lawsuits filed in the State of Connecticut and the State ...
Cached Biology Technology:PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 2PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 3PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants 4CuraGen Reports Second Quarter 2009 Financial Results 2CuraGen Reports Second Quarter 2009 Financial Results 3CuraGen Reports Second Quarter 2009 Financial Results 4CuraGen Reports Second Quarter 2009 Financial Results 5CuraGen Reports Second Quarter 2009 Financial Results 6CuraGen Reports Second Quarter 2009 Financial Results 7CuraGen Reports Second Quarter 2009 Financial Results 8
(Date:8/20/2015)... The wearable technology market has traditionally ... healthy. However, wearable technology has the potential to ... improve diagnostic capabilities and therapeutic outcomes. Today, Leaf ... Technologies Conference 2015 , where Barrett Larson ... healthcare.    "Over the past decade, ...
(Date:8/18/2015)... , Aug. 17, 2015 Research and ... of the "Global Biometric Authentication & Identification ... Estimation & Forecast, 2015-2020" report to their ... and identification systems market is expected to grow ... to 2020 and generate over $25 billion (approximately) ...
(Date:8/12/2015)... Calif. , Aug. 12, 2015  Synaptics ... of human interface solutions, today announced that four ... announced Match-in-Sensor solution, have officially been named FIDO ... As part of the certification, Synaptics, Natural ID™ ... 1.0 Universal Authentication Framework (UAF) standard and are ...
Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... long-standing tradition in protecting areas on land. But unfortunately, ... sea-shore and under water," says meteorologist Marianne Nitter at ... "These may include mooring and landing sites, jetties, boat-houses, ... inform us about prehistoric maritime culture and our ancestors, ...
... Adapting a chemical used to deliver medicines through ... Levar has developed a way to protect plants from ... hot pepper concentrate through the roots of young plants, ... said Elizabeth Summa, president of Repellex USA, which licensed ...
... Institute of Food Research scientists have discovered an unexpected synergy ... to find ways to slow down fat digestion, and ultimately ... the fat in processed foods is eaten in the form ... said Dr Peter Wilde from the Institute of Food Research, ...
Cached Biology News:New ways to chart our maritime past 2New ways to chart our maritime past 3U of M licenses unique plant protection product 2
... T4 Polynucleotide Kinase catalyzes ... from ATP to the 5-terminus ... bearing a 5-hydroxyl group. The ... coli, may be used to ...
... Freezers for IVF are designed for human ... ease of setup and operation, and convenience. ... are continuously displayed on the control panel. ... are printed by way of the thermal ...
... venom Description: Phosphodiesterase I (venom ... studying nucleic acid structure and ... 5'-mononucleotides from 3'-hydroxy-terminated ribo-oligonucleotides and ... cleaves ADP-ribosylated proteins at the ...
... Life Science Rotarods are used to assess the ... fatigue resistance on mice and rats using one ... user friendly; the animals are placed on textured ... onto the individual sensing platforms below, its test ...
Biology Products: